Rénibus Therapeutics

Rénibus Therapeutics is a privately held clinical-stage biopharmaceutical company headquartered in Southlake, Texas, developing treatments for cardio, renal and metabolic disease. Its pipeline is led by veverimer, a non-absorbed polymer in Phase 3 for metabolic acidosis in chronic kidney disease, and RBT-1 (stannic protoporfin / iron sucrose), a first-in-class intravenous pharmacologic preconditioning agent given 24-48 hours before non-emergent cardiac surgery to reduce post-operative complications, which holds FDA Breakthrough Therapy and Fast Track designations and completed the pivotal Phase 3 PROTECT trial. The company publishes a corporate marketing site, a news and events feed, an expanded access policy and patient information, but operates no developer program, public API, or machine-readable API contract.

Rénibus Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Life Sciences, and Healthcare.

Rénibus Therapeutics’ developer surface includes engineering blog, support, and 8 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.6/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiopharmaceuticalPharmaceuticalsLife SciencesHealthcareClinical TrialsNephrologyCardiovascular

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 11.6/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 1.1 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/renibus-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Renibus Therapeutics Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 5

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 BlogRSS
BlogRSS
 Careers
Careers

Other 1

Properties that don't map to a standard resource type

SecondaryMarket
SecondaryMarket

Source (apis.yml)

apis.yml Raw ↑ 
aid: renibus-therapeutics
name: Rénibus Therapeutics
description: Rénibus Therapeutics is a privately held clinical-stage biopharmaceutical company headquartered in Southlake,
  Texas, developing treatments for cardio, renal and metabolic disease. Its pipeline is led by veverimer, a non-absorbed polymer
  in Phase 3 for metabolic acidosis in chronic kidney disease, and RBT-1 (stannic protoporfin / iron sucrose), a first-in-class
  intravenous pharmacologic preconditioning agent given 24-48 hours before non-emergent cardiac surgery to reduce post-operative
  complications, which holds FDA Breakthrough Therapy and Fast Track designations and completed the pivotal Phase 3 PROTECT
  trial. The company publishes a corporate marketing site, a news and events feed, an expanded access policy and patient information,
  but operates no developer program, public API, or machine-readable API contract.
image: https://www.renibus.com/wp-content/uploads/2022/10/renibus-therapeutics-logo-retina.png
url: https://raw.githubusercontent.com/api-evangelist/renibus-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Life Sciences
- Healthcare
- Clinical Trials
- Nephrology
- Cardiovascular
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.renibus.com/
- type: About
  url: https://www.renibus.com/about-us/
- type: Blog
  url: https://www.renibus.com/news-and-events/
- type: BlogRSS
  url: https://www.renibus.com/feed/
- type: Support
  url: https://www.renibus.com/contact-us/
- type: PrivacyPolicy
  url: https://www.renibus.com/privacy-policy/
- type: TermsOfService
  url: https://www.renibus.com/terms-and-conditions/
- type: Careers
  url: https://www.renibus.com/careers/
- type: DomainSecurity
  url: security/renibus-therapeutics-domain-security.yml
- type: SecondaryMarket
  url: https://forgeglobal.com/renibus-therapeutics_stock/
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Rénibus is a clinical-stage drug developer whose entire public web presence is a ten-page WordPress/Avada marketing
    site (about, approach, patients, news, careers, contact, policies) with no developer, docs, or API section; api./developer./docs./portal.renibus.com
    do not resolve in DNS and every contract-discovery path returns 404 — the only machine-readable endpoint on the host is
    the generic WordPress /wp-json/ CMS route, which is not a product API.
  evidence:
  - url: https://www.renibus.com/openapi.json
    status: 404
  - url: https://www.renibus.com/.well-known/agent-card.json
    status: 404
  - url: https://www.renibus.com/.well-known/security.txt
    status: 404
  - url: https://www.renibus.com/llms.txt
    status: 404
  - url: https://www.renibus.com/sitemap.xml
    status: 200
  checked: '2026-08-05'